Should we be using DPP4 inhibitor therapy more for treatment of Type 2 diabetes mellitus given its outperformance in keeping glucose in range compared to other glucose lowering agents like glimepiride for patients who cannot afford GLP 1 R agonist therapy or SGLT2 inhibitor therapy?
Thirumalai A, Hirsch IB. Glycemic Trends From Continuous Glucose Monitoring With DPP-4 Inhibitor Therapy in Patients With Type 2 Diabetes-Redefining the Role of an Overlooked Agent. Diabetes Care. 2026 Jun 1;49(6):940-942. doi: 10.2337/dci26-0040. PMID: 42160610.